Page 74 - Read Online

Bobronnikova Biomarker of metabolic disorders and cardiovascular remodeling

endothelial response to diabetes reveals a role for galectin-3. Physiol 2000;106:473-81.
Genomics 2011;43:1144-52. 27. du Cailar G, Pasquié JL, Ribstein J, Mimran A. Left ventricular
19. Karlsen AE, Størling ZM, Sparre T, Larsen MR, Mahmood A, adaptation to hypertension and plasma renin activity. J Hum Hypertens
Størling J, Roepstorff P, Wrzesinski K, Larsen PM, Fey S, Nielsen K, 2000;14:181-8.
Heding P, Ricordi C, Johannesen J, Kristiansen OP, Christensen UB, 28. Seferovic JP, Lalic NM, Floridi F, Tesic M, Seferovic PM, Giga V,
Kockum I, Luthman H, Nerup J, Pociot F. Immune-mediated beta-cell Lalic K, Jotic A, Jovicic S, Colak E, Salerno G, Cardelli P, Di Somma
destruction in vitro and in vivo-a pivotal role for galectin-3. Biochem S. Structural myocardial alterations in diabetes and hypertension: the
Biophys Res Commun 2006;344:406-15. role of galectin-3. Clin Chem Lab Med 2014;52:1499-505.
20. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. 29. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Increased levels
Galectin-3 in diabetic patients. Clin Chem Lab Med 2014;52:1413-23. of galectin-3 were associated with prediabetes and diabetes: new risk
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, factor? J Endocrinol Invest 201;38:527-33.
Turner RC. Homeostasis model assessment: insulin resistance 30. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC,
and beta-cell function from fasting plasma glucose and insulin van Gilst WH, Hillege HL, Bakker SJ, van der Harst P. The fibrosis
concentrations in man. Diabetologia 1985;28:412-9. marker galectin-3 and outcome in the general population. J Intern
22. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality Med 2012;272:55-64.
from coronary heart disease in subjects with type 2 diabetes and in 31. Ohkura T, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto
nondiabetic subjects with and without prior myocardial infarction. N N, Matsuzawa K, Izawa S, Ohkura H, Ueta E, Kato M, Miyoshi E,
Engl J Med 1998;339:229-34. Taniguchi S, Yamamoto K. Low serum galectin-3 concentrations
23. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of are associated with insulin resistance in patients with type 2 diabetes
intervention to inhibit progression of carotid intima-media thickness mellitus. Diabetol Metab Syndr 2014;6:106.
in patients with type 2 diabetes mellitus. Stroke 2006;37:2420-7. 32. Ozturk D, Celik O, Satilmis S, Aslan S, Erturk M, Cakmak HA,
24. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li Kalkan AK, Ozyilmaz S, Diker V, Gul M. Association between serum
JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. galectin-3 levels and coronary atherosclerosis and plaque burden/
Nicotinic acetylcholine receptor alpha7 subunit is an essential structure in patients with type 2 diabetes mellitus. Coron Artery Dis
regulator of inflammation. Nature 2003;421:384-8. 2015;26:396-401.
25. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. 33. Meluzín J, Tomandl J. Can biomarkers help to diagnose early
Am J Med Sci 2001;321:242-8. heart failure with preserved ejection fraction? Dis Markers
26. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2015;2015:426045.

Vessel Plus ¦ Volume 1 ¦ June 27, 2017 67